Cargando…

Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant.

To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment. Fifteen patients (median age 13 years; range 1–20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabrizio, Vanessa A., Kernan, Nancy A., Boulad, Farid, Cancio, Maria, Allen, Jennifer, Higman, Meghan, Margossian, Steven P., Mauguen, Audrey, Prockop, Susan, Scaradavou, Andromachi, Shah, Niketa, Spitzer, Barbara, Stieglitz, Elliot, Yeager, Nicholas, O’Reilly, Richard J., Brentjens, Renier J., Boelens, Jaap Jan, Curran, Kevin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606268/ https://www.ncbi.nlm.nih.gov/pubmed/32390002 http://dx.doi.org/10.1038/s41409-020-0926-1

Ejemplares similares

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Association between busulfan exposure and survival in patients undergoing a CD34(+) selected stem cell transplantation
por: Tamari, Roni, et al.
Publicado: (2023)

Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors
por: Anur, Praveen, et al.
Publicado: (2016)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Cord blood power and the definition of success after BMT
por: Boelens, Jaap Jan, et al.
Publicado: (2022)

Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients
por: Troullioud Lucas, Alexandre G., et al.
Publicado: (2023)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Cytokine IL-36γ Improves CAR T Cell Functionality and Induces Endogenous Anti-Tumor Response
por: Li, Xinghuo, et al.
Publicado: (2020)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
por: Jaspers, Janneke E., et al.
Publicado: (2023)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
por: Prockop, Susan E., et al.
Publicado: (2023)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

How do CARs work?: Early insights from recent clinical studies targeting CD19
por: Davila, Marco L., et al.
Publicado: (2012)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor
por: Forlenza, Christopher J., et al.
Publicado: (2015)

Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells
por: Dickson, Mark A., et al.
Publicado: (2014)

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
por: Avanzi, Mauro P., et al.
Publicado: (2018)

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
por: Park, Jae H, et al.
Publicado: (2018)

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
por: Chan, Shuk Ying, et al.
Publicado: (2021)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

Further proof of the plasticity of adult stem cells and their role in tissue repair
por: Prockop, Darwin J.
Publicado: (2003)

Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
por: Wang, Xiuyan, et al.
Publicado: (2021)

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results
por: Boulad, Farid, et al.
Publicado: (2018)

Are Clinical Trials With Mesenchymal Stem/Progenitor Cells too Far Ahead of the Science? Lessons From Experimental Hematology
por: Prockop, Darwin J, et al.
Publicado: (2014)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
por: Gardner, Thomas J., et al.
Publicado: (2020)

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021)

Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation
por: Spel, Lotte, et al.
Publicado: (2013)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
por: Plantinga, Maud, et al.
Publicado: (2014)

Morbidity and Mortality Associated With Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplant: Too Little Defense or Harmful Immunity?
por: Versluys, Anne Birgitta, et al.
Publicado: (2018)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

INTRACELLULAR ACCUMULATION OF PROTOCOLLAGEN AND EXTRUSION OF COLLAGEN BY EMBRYONIC CARTILAGE CELLS
por: Cooper, George W., et al.
Publicado: (1968)

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation
por: Teshima, Takanori, et al.
Publicado: (2023)

Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization
por: Boelens, Jaap Jan, et al.
Publicado: (2020)

Flying cars economically favor battery electric over fuel cell and internal combustion engine
por: Liu, Ming, et al.
Publicado: (2023)

Stanniocalcin-1 Regulates Extracellular ATP-Induced Calcium Waves in Human Epithelial Cancer Cells by Stimulating ATP Release from Bystander Cells
por: Block, Gregory J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7gpsc2ifqmvo3kggjlmm22q6jn